Literature DB >> 22324973

Tedizolid (TR-701): a new oxazolidinone with enhanced potency.

Zeina A Kanafani1, G Ralph Corey.   

Abstract

INTRODUCTION: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. AREAS COVERED: This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed. EXPERT OPINION: Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22324973     DOI: 10.1517/13543784.2012.660250

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  17 in total

Review 1.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

2.  In Vitro Activity of Tedizolid against Mycobacterium tuberculosis.

Authors:  Pilar Ruiz; Manuel Causse; Manuel Vaquero; Manuel Casal
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  Antimicrobial stewardship and linezolid.

Authors:  Pauline Guillard; Arnaud de La Blanchardière; Vincent Cattoir; Marc-Olivier Fischer; Renaud Verdon; Guillaume Saint-Lorant
Journal:  Int J Clin Pharm       Date:  2014-08-19

4.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

5.  In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

6.  Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.

Authors:  Jordan R Smith; Juwon Yim; Seth Rice; Kyle Stamper; Razie Kebriaei; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  In Vitro Susceptibility Testing of Tedizolid against Isolates of Nocardia.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

8.  Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections.

Authors:  Elaine Wong; Saba Rab
Journal:  P T       Date:  2014-08

9.  Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.

Authors:  S Flanagan; S L Minassian; D Morris; R Ponnuraj; T C Marbury; H W Alcorn; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

10.  In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.

Authors:  D J Biedenbach; S K Bouchillon; B Johnson; J Alder; D F Sahm
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-09-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.